Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed biliary tract cancer~  * Locally advanced, unresectable, or metastatic disease~* Metastatic adenocarcinoma with clinical documentation of gallbladder or bile tree involvement with no evidence of another primary adenocarcinoma allowed~* Measurable or nonmeasurable disease~* Treatable biliary duct obstruction must be relieved by either internal endoscopic drainage/stenting or palliative bypass surgery before study entry~* Symptomatic biliary tract cancer and has at least 1 of the following:~  * Karnofsky 60-80%~ * Baseline analgesic consumption at least 10 mg of morphine equivalents per day~ * Baseline pain intensity score of at least 20 mm out of a possible 100 mm~* No prior or concurrent CNS metastasis~PATIENT CHARACTERISTICS:~Age~* 18 to 80~Performance status~* See Disease Characteristics~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10.0 g/dL~Hepatic~* Bilirubin no greater than 4 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 5 times ULN~* AST and ALT no greater than 5 times ULN~Renal~* Creatinine clearance greater than 50 mL/min~Cardiovascular~* No uncontrolled cardiovascular disease~Gastrointestinal~* Able to ingest oral medication~* No malabsorption syndrome~* No intractable nausea and/or vomiting~* No partial small bowel obstruction~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 year after study participation~* No active autoimmune disease~* No uncontrolled diabetes~* No known hypersensitivity to fluorouracil~* No known dihydropyrimidine dehydrogenase deficiency~* No definitive contraindication to corticosteroids~* No prior significant neurologic or psychiatric disorders (e.g., psychotic disorders, dementia, or seizures) that would preclude understanding or providing informed consent~* No prior severe reaction to fluoropyrimidine therapy~* No psychiatric disorder, cognitive dysfunction, or language problem that would preclude filling out the quality of life questionnaire or patient diary~* No other serious underlying medical condition that would preclude study participation~* No other malignancy within the past 5 years except nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior biologic therapy~* No prior immunotherapy~Chemotherapy~* No prior chemotherapy for advanced/metastatic disease~* No prior palliative chemotherapy~Endocrine therapy~* No concurrent megestrol~Radiotherapy~* More than 4 weeks since prior radiotherapy~* No concurrent radiotherapy~  * Treatment of a single painful lesion allowed~Surgery~* See Disease Characteristics~* Prior Whipple procedure allowed~* Prior duodenal bypass allowed~* No concurrent endoscopic or external biliary drainage as a consequence of progressive malignant bile duct obstruction~  * Drainage as a consequence of nonmalignant bile duct obstruction allowed~Other~* More than 30 days since prior treatment within a clinical study~* No other concurrent anticancer drugs~* No other concurrent investigational drugs~* No concurrent sorivudine or its chemically-related analogues (e.g., lamivudine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Capecitabine plus Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).